Who Pays My Doctor?

Healthcare provider profile · identity verified

Mitchell Lyle Glaser, MD.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · CHICAGO, IL · NPI 1598789521

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Mitchell Lyle Glaser, MD. received $255,531.13 in general payments during 2025 across 479 reported records.

E.R. Squibb & Sons, L.L.C. accounted for 43.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 22 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Spravato.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Spravato by this doctor in 2024.

Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 586 records involving 456 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Spravato by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$255,531.13

479 reported records · 19 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $112,245.7143.9%1482025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $58,996.7923.1%762025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $27,986.7510.9%492025
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $20,147.107.9%352025
ABBVIE INC. Unresolved — no canonical attribution shown $19,404.577.6%472025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $14,805.215.8%222025
Alkermes, Inc. Unresolved — no canonical attribution shown $310.740.1%172025
Supernus Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $291.070.1%222025
Lundbeck LLC Unresolved — no canonical attribution shown $284.990.1%122025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $275.650.1%212025
Janssen Scientific Affairs, LLC Unresolved — no canonical attribution shown $200.000.1%12025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $163.280.1%62025
Corium, LLC Unresolved — no canonical attribution shown $122.370.1%82025
HARMONY BIOSCIENCES LLC Unresolved — no canonical attribution shown $94.020.0%52025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $66.630.0%32025
Collegium Pharmaceutical, Inc. Unresolved — no canonical attribution shown $64.680.0%42025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $30.150.0%12025
IDORSIA PHARMACEUTICALS US INC Unresolved — no canonical attribution shown $23.140.0%12025
C2N Diagnostics, LLC Unresolved — no canonical attribution shown $18.280.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$191,675.0064
Consulting Fee$31,216.5012
Travel and Lodging$22,059.1472
Food and Beverage$10,580.49331

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $94,123.87 123 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $58,996.79 76 2025
Source payment records
SPRAVATO
Normalized: spravato		 Drug Janssen Pharmaceuticals, Inc, Janssen Scientific Affairs, LLC $28,062.44 44 2025
Source payment records
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $20,147.10 35 2025
Source payment records
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $17,971.70 45 2025
Source payment records
UZEDY
Normalized: uzedy		 Drug Teva Pharmaceuticals USA, Inc. $14,747.65 20 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc. $342.52 14 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $310.74 17 2025
Source payment records
Qelbree
Normalized: qelbree		 Drug Supernus Pharmaceuticals, Inc. $291.07 22 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $282.21 16 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $275.65 21 2025
Source payment records
INVEGA SUSTENNA
Normalized: invega sustenna		 Drug Janssen Pharmaceuticals, Inc $124.31 6 2025
Source payment records
Azstarys
Normalized: azstarys		 Drug Corium, LLC $122.37 8 2025
Source payment records
ABILIFY ASIMTUFII
Normalized: abilify asimtufii		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc. $105.75 4 2025
Source payment records
WAKIX
Normalized: wakix		 Drug HARMONY BIOSCIENCES LLC $94.02 5 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $66.63 3 2025
Source payment records
Jornay PM
Normalized: jornay pm		 Drug Collegium Pharmaceutical, Inc. $64.68 4 2025
Source payment records
AUSTEDO XR
Normalized: austedo xr		 Drug Teva Pharmaceuticals USA, Inc. $57.56 2 2025
Source payment records
TRINTELLIX
Normalized: trintellix		 Drug Takeda Pharmaceuticals U.S.A., Inc. $30.15 1 2025
Source payment records
ABILIFY MAINTENA
Normalized: abilify maintena		 Drug Otsuka America Pharmaceutical, Inc. $28.53 1 2025
Source payment records
Quviviq
Normalized: quviviq		 Drug IDORSIA PHARMACEUTICALS US INC $23.14 1 2025
Source payment records
PRECIVITYAD2
Normalized: precivityad2		 Device C2N Diagnostics, LLC $18.28 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
CAPLYTA
caplyta		 2025 Caplyta 2024 11
Beneficiary count suppressed		 exact normalized Medicare Part D
SPRAVATO
spravato		 2025 Spravato 2024 145
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
Exact reporting entity; no affiliate inference		 2025 CAPLYTA
open payments reported associated product		 CMS Open Payments — General Payments
211855 supporting records · 46143 recipient NPIs · example record 1241243071 		Caplyta · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS
Janssen Pharmaceuticals, Inc
Exact reporting entity; no affiliate inference		 2025 Caplyta
open payments reported associated product		 CMS Open Payments — General Payments
11 supporting records · 9 recipient NPIs · example record 1174547314 		Caplyta · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS
Janssen Pharmaceuticals, Inc
Exact reporting entity; no affiliate inference		 2025 SPRAVATO
open payments reported associated product		 CMS Open Payments — General Payments
43813 supporting records · 17025 recipient NPIs · example record 1174223254 		Spravato · 2024
Exact normalized brand match · 1 Part D row		 145 suppressed by CMS
Janssen Scientific Affairs, LLC
Exact reporting entity; no affiliate inference		 2025 SPRAVATO
open payments reported associated product		 CMS Open Payments — General Payments
586 supporting records · 456 recipient NPIs · example record 1174147619 		Spravato · 2024
Exact normalized brand match · 1 Part D row		 145 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
OlanzapineOlanzapine216suppressed
Quetiapine FumarateQuetiapine Fumarate216suppressed
Divalproex SodiumDivalproex Sodium156suppressed
SpravatoEsketamine Hcl145suppressed
ClozapineClozapine119suppressed
Benztropine MesylateBenztropine Mesylate101suppressed
AripiprazoleAripiprazole80suppressed
Lithium CarbonateLithium Carbonate75suppressed
Citalopram HbrCitalopram Hydrobromide64suppressed
RisperidoneRisperidone58suppressed
Prazosin HclPrazosin Hcl50suppressed
OxcarbazepineOxcarbazepine43suppressed
CarbamazepineCarbamazepine37suppressed
Amlodipine BesylateAmlodipine Besylate33suppressed
HaloperidolHaloperidol32suppressed
Sertraline HclSertraline Hcl32suppressed
Fluoxetine HclFluoxetine Hcl26suppressed
Valproic AcidValproic Acid (As Sodium Salt)24suppressed
Levothyroxine SodiumLevothyroxine Sodium23suppressed
LorazepamLorazepam23suppressed
Hydroxyzine HclHydroxyzine Hcl18suppressed
Memantine HclMemantine Hcl18suppressed
AmantadineAmantadine Hcl17suppressed
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine17suppressed
Bupropion XlBupropion Hcl16suppressed
AlprazolamAlprazolam15suppressed
Zolpidem TartrateZolpidem Tartrate15suppressed
GabapentinGabapentin14suppressed
Haloperidol DecanoateHaloperidol Decanoate12suppressed
Metformin HclMetformin Hcl12suppressed
CaplytaLumateperone Tosylate11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $255,531.13 · 479 records E.R. Squibb & Sons, L.L.C. ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, PRECIVITYAD2, Qelbree, Quviviq, REXULTI, SPRAVATO, TRINTELLIX, UZEDY, VRAYLAR, WAKIX 4 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error